Table 2.
 Hypotension rates with tamsulosin, according to risk window of exposure and between and within patient methodology
| No of men | No of events | No of person years | Rate of hypotension per 10 000 person years* | Rate ratio (95% CI) | |
|---|---|---|---|---|---|
| Model 1: Cohort analysis | |||||
| New use (weeks 1-4) | 324 255 | 179 | 22 950 | 78.0 | 2.12 (1.29 to 3.04) |
| New use (weeks 5-8) | 278 283 | 74 | 15 116 | 49.0 | 1.51 (1.04 to 2.18) |
| New use (weeks 9-12) | 174 599 | 63 | 14 373 | 43.8 | 1.16 (0.83 to 1.61) |
| Restarting treatment (weeks 1-4) | 103 145 | 74 | 14 641 | 50.5 | 1.84 (1.46 to 2.33) |
| Restarting treatment (weeks 5-8) | 96 630 | 69 | 13 271 | 52.0 | 1.85 (1.45 to 2.36) |
| Restarting treatment (weeks 9-12) | 77 418 | 39 | 10 398 | 37.5 | 1.34 (0.97 to 1.84) |
| Maintenance treatment | 151 307 | 520 | 149 527 | 34.8 | 1.19 (1.07 to 1.32) |
| Model 2: Self controlled case series | |||||
| New use (weeks 1-4) | 2248 | 185 | 167 | 110.8 | 2.56 (2.15 to 3.05) |
| New use (weeks 5-8) | 2076 | 79 | 118 | 67.2 | 1.66 (1.30 to 2.11) |
| New use (weeks 9-12) | 1404 | 68 | 116 | 58.6 | 1.54 (1.19 to 2.01) |
| Restarting treatment (weeks 1-4) | 1104 | 80 | 181 | 44.2 | 1.58 (1.24 to 2.01) |
| Restarting treatment (weeks 5-8) | 1070 | 74 | 172 | 43.0 | 1.60 (1.25 to 2.05) |
| Restarting treatment (weeks 9-12) | 912 | 42 | 133 | 31.6 | 1.19 (0.86 to 1.64) |
| Maintenance treatment | 1357 | 651 | 1923 | 33.9 | 1.38 (1.21 to 1.57) |
*Incidence of hypotension for the cohort represents absolute incidence in the study population, while incidence in the self controlled case series represents relative incidence in the cases.